Michael Brooks
President at EDESA BIOTECH, INC.
Net worth: 18 252 $ as of 2024-03-30
Profile
Michael Brooks is currently the President at Edesa Biotech, Inc. He previously worked as the Director of Business Development at Cipher Pharmaceuticals, Inc. from 2010 to 2015.
He also held positions at Edesa Biotech, Inc. (Old) and Edesa Biotech Research, Inc. In terms of education, Dr. Brooks holds an MBA from the Rotman School of Management and undergraduate and doctorate degrees from the University of Toronto.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
EDESA BIOTECH, INC.
0.14% | 2023-12-22 | 4,354 ( 0.14% ) | 18 252 $ | 2024-03-30 |
Michael Brooks active positions
| Companies | Position | Start |
|---|---|---|
| EDESA BIOTECH, INC. | President | 2019-06-06 |
Former positions of Michael Brooks
| Companies | Position | End |
|---|---|---|
| CIPHER PHARMACEUTICALS INC. | Corporate Officer/Principal | 2014-12-31 |
| Edesa Biotech Research, Inc. | Corporate Officer/Principal | - |
Edesa Biotech, Inc. (Old)
 Edesa Biotech, Inc. (Old) Pharmaceuticals: MajorHealth Technology Edesa Biotech, Inc. engages in the development of treatments for dermatological and anorectal diseases. Its product pipeline is based on non-steroidal molecules for the treatment of allergic contact dermatitis, hemorrhoids, and anal fissures. The company was founded by Par Nijhawan in 2015 and is headquartered in Markham, Canada. | President | - |
Training of Michael Brooks
| Rotman School of Management | Masters Business Admin |
| University of Toronto | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| CIPHER PHARMACEUTICALS INC. | Health Technology |
| EDESA BIOTECH, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Edesa Biotech, Inc. (Old)
Edesa Biotech, Inc. (Old) Pharmaceuticals: MajorHealth Technology Edesa Biotech, Inc. engages in the development of treatments for dermatological and anorectal diseases. Its product pipeline is based on non-steroidal molecules for the treatment of allergic contact dermatitis, hemorrhoids, and anal fissures. The company was founded by Par Nijhawan in 2015 and is headquartered in Markham, Canada. | Health Technology |
| Edesa Biotech Research, Inc. |
- Stock Market
- Insiders
- Michael Brooks
